- In July 2023, Viatris Inc., in partnership with Kindeva Drug Delivery, launched the first FDA-approved generic version of Symbicort, called Breyna, for patients with asthma and COPD. This inhalation aerosol is an affordable treatment option, expanding access to effective respiratory care for individuals managing these chronic respiratory conditions
- In January 2023, AstraZeneca announced the approval of Airsupra (albuterol/budesonide) for as-needed treatment or prevention of bronchoconstriction. This inhaler also helps reduce the risk of asthma exacerbations in the U.S., offering patients with asthma a more effective and accessible option for managing their condition, enhancing quality of life and symptom control
- In June 2022, United Therapeutics Corporation received FDA approval for Tyvaso DPI (treprostinil) inhalation powder, designed to treat pulmonary arterial hypertension and pulmonary hypertension related to interstitial lung disease. This approval marked a significant advancement in therapeutic options, providing a new treatment avenue for patients suffering from these serious and complex lung conditions
- In June 2022, AstraZeneca unveiled plans to build a production facility in Qingdao, China, to manufacture Breztri, an aerosol inhalant for treating COPD. This product has recently been added to China’s national reimbursement drug list, increasing accessibility to this crucial treatment and underscoring AstraZeneca’s commitment to enhancing healthcare in China
